{"ticker": {"uuid": "a0f57010-d7d9-4d55-b081-7ffc13c2e52e", "symbol": "GERN", "name": "Geron Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Geron (GERN) Is Signaling Commercial Ambition, Not Just Handing Out Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxNN3FHeWZmdGRzOUFOUGlFQWlpVWlfYlRmTUMwOHZaTG5QZ2I0VEp1MFNWd1N1amxNdDNMTWlCT2hnc1dmM2tSY0Z0NTR3SzZsY3E1RnZIdHBwT2hvY1FzOVRWV1lqSW9mZHB4cGlIUklKN3pMWGd3Q1l5ZlFTdWRyZHhKNW9NaGNKY3dObmFqd1dyX3ctOE9yLWlsNTdZN1dmU2JZc3dfRzVuek1lNkF0TGgtSW9LSzJ3Q0tGTFRRQmJPREpCTUhCNG5EX0N4V0w0NnpQVHlqYzRWNmlKSlowNGs5Wk9Cd3N4ZkNDakJXSE1EZzdKaHltMVJwdm84NFlrMHU5T3VRT0tqeWZ6cjdGaWM5UE1rT0xMWF9wYTM5dmxnMnpVWk1TYmdGOE5jaGQyRFlMRFhtOWoyd2JKNlZ0NUZLZ2_SAcQCQVVfeXFMTTdxR3lmZnRkczlBTlBpRUFpaVVpX2JUZk1DMDh2WkxuUGdiNFRKdTBTVndTdWpsTXQzTE1pQk9oZ3NXZjNrUmNGdDU0d0s2bGNxNUZ2SHRwcE9ob2NRczlUVldZaklvZmRweHBpSFJJSjd6TFhnd0NZeWZRU3VkcmR4SjVvTWhjSmN3Tm5handXcl93LThPci1pbDU3WTdXZlNiWXN3X0c1bnpNZTZBdExoLUlvS0syd0NLRkxUUUJiT0RKQk1IQjRuRF9DeFdMNDZ6UFR5amM0VjZpSkpaMDRrOVpPQndzeGZDQ2pCV0hNRGc3Smh5bTFScHZvODRZazB1OU91UU9LanlmenI3RmljOVBNa09MTFhfcGEzOXZsZzJ6VVpNU2JnRjhOY2hkMkRZTERYbTlqMndiSjZWdDVGS2dv?oc=5", "source_name": "AlphaStreet", "published_at": "2026-07-15T11:50:22+00:00", "published_display": "15 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Geron Corporation announced an inducement grant in the form of a stock option to purchase 1,700,000 shares of its common stock for Chinmaya Rath, the new Chief Business Officer. The grant, made on July 13, 2026, has an exercise price of $1.42 per share and vests over four years, ", "url": "https://sg.finance.yahoo.com/news/geron-corporation-reports-inducement-grant-202600682.html", "source_name": "Market source", "published_at": "2026-07-14T20:26:00", "published_display": "14 Jul 2026 20:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron's New Business Chief Gets Option on 1.7M Shares", "summary": "Geron (GERN) granted a stock option to its new Chief Business Officer, Chinmaya Rath, entitling him to purchase 1.7 million shares of common stock. This inducement award, detailed in a recent report, has an exercise price of $1.42 per share, matching the closing price on the gran", "url": "https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-do92xlx06muk.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:17:30", "published_display": "14 Jul 2026 20:17", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Grants Inducement Stock Options to New Employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPNVFOSElFdXl0R2l0NmNWWFhaeXNaUmd5ajJlNzhwRkNrNDQ0TkFUV2h1bjJnQUZHUzlpbVo2bmJXSF8tV3hoNkw4ZV9SOXpLOThsQk50QnFWemt0RWd5QXRBQjhTOHNxSG5EMEpGNUp4ZEZxTmZUaTEwMUE4bG5KUFhMdF9kMEI0T252T2VKT3Nzc1liU2RxRWNERVBWX3F1?oc=5", "source_name": "Market source", "published_at": "2026-07-14T10:34:02+00:00", "published_display": "14 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth", "summary": "Geron (Nasdaq: GERN) has appointed Chinmaya Rath as its new Chief Business Officer, effective July 13, 2026. Rath brings over 25 years of biopharma leadership experience from companies like Novartis and Cellworks, and will focus on maximizing RYTELO's global value and expanding G", "url": "https://www.stocktitan.net/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-39rh8q718wzc.html", "source_name": "Stock Titan", "published_at": "2026-07-13T17:12:17", "published_display": "13 Jul 2026 17:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Geron appoints Chinmaya Rath as chief business officer", "summary": "Geron Corporation has appointed Chinmaya Rath as Chief Business Officer, leveraging his 25 years of biopharmaceutical leadership experience from companies like Novartis and Cellworks. Rath will contribute to the commercial-stage company, which markets RYTELO for myelodysplastic s", "url": "https://www.investing.com/news/company-news/geron-appoints-chinmaya-rath-as-chief-business-officer-93CH-4788440", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:41", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Announces Appointment of Chinmaya Rath as Chief Business Officer", "summary": "Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharmaceutical leadership experience and will focus on maximizing the value of Geron's drug RYTELO and exploring new opportunities to expand the company's hematology p", "url": "https://ca.finance.yahoo.com/news/geron-announces-appointment-chinmaya-rath-120000011.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-13T12:09:41", "published_display": "13 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Geron Corporation Stocks", "summary": "This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Geron Corporation (0IV3 on the London Stock Exchange). It details various ETFs, including their market value, weight of Geron stock, issuer, management style, expense ratio, assets unde", "url": "https://www.tradingview.com/symbols/LSE-0IV3/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T00:40:51", "published_display": "09 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron stock leans on its myelofibrosis story", "summary": "Geron's stock performance is closely linked to the commercial rollout of its lead product, Rytelo, for myelofibrosis. The biotechnology company, listed on Nasdaq, focuses on blood-cancer therapies, with execution in sales adoption and physician uptake being crucial for its market", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-stock-leans-on-its-myelofibrosis-story/69679846", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:43:46", "published_display": "03 Jul 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN News | GERON CORP (NASDAQ:GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1HNTJFakppZ0QtdER5ZEZMVEdnNVIzaXN2eUhyZXRTaUd6ZTc5TzF6ejBFRDhuMlczWkkwRVl2S0NwOTJFVHhwX2RLbmJ1akE0NE80a1Y0THpQSTQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees", "summary": "Geron Corp. (GERN) director Robert J. Spiegel received a grant of 6,103 shares of common stock on June 30, 2026, as compensation for his quarterly board retainer and committee fees. The shares were valued at $1.28 each, based on the closing price of the company's stock that day. ", "url": "https://www.stocktitan.net/sec-filings/GERN/form-4-geron-corp-insider-trading-activity-2d487d1a043b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:39", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Geron Corporation For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Geron Corporation on July 1st. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a ", "url": "https://ca.investing.com/news/stock-market-news/form-4-geron-corporation-for-1-july-93CH-4717234", "source_name": "Investing.com Canada", "published_at": "2026-07-01T21:40:39", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSndRWF8zQVVlWFNnQVJic2N1OXFqOERxV2I0bW5Nc2U0OUMwckxETjJISy1pRDVobDliM1FPWjRiMktITDJuX0FOUjFDSGhXeWhEdTJQRTdnNUFjS1NNUGZjYmdfSlBIaGphVVZMSW53eTd3LUZRNGR2RmpzYWdwanZEUFhfdmRqbHA0Z0FDVENjWi1Nd1FVV2Z1TXNJajE4cnZGc1ZfaEZqVXdWMDJZVVdwVmFBTExS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Geron Corporation (GERN) stock, indicating current stock performance, analyst opinions, and key financial metrics. It highlights GERN's present stock price, recent percentage changes, historical highs and lows, and upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-GERN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:49", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Stock Steadies As Geron Builds Commercial Momentum", "summary": "Geron Corporation (GERN) stock is experiencing a 7.14% increase due to positive sentiment surrounding its late-stage blood cancer therapy. The company has granted significant stock options to new employees, signaling aggressive talent acquisition, and is demonstrating commercial ", "url": "https://stockstotrade.com/news/geron-corporation-gern-news-2026_06_22/", "source_name": "StocksToTrade", "published_at": "2026-06-22T17:40:18", "published_display": "22 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Geron Corporation announced inducement grants of stock options to eight new employees, as specified under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. Geron is a comm", "url": "https://www.manilatimes.net/2026/06/19/tmt-newswire/globenewswire/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2368826", "source_name": "The Manila Times", "published_at": "2026-06-20T10:39:38", "published_display": "20 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron dangles 690,000 options to recruit eight new employees", "summary": "Geron (Nasdaq: GERN) granted 690,000 stock options to eight new employees as inducement awards on June 17, 2026. The options have an exercise price of $1.23 per share, matching the closing price on the grant date, and vest over four years. This move resulted in a 6.35% increase i", "url": "https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-ex89egsh2038.html", "source_name": "Stock Titan", "published_at": "2026-06-18T15:40:35", "published_display": "18 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Geron Corp (GERN), listing major institutional shareholders like RA Capital Management and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent changes in shareholdings ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T15:13:49", "published_display": "18 Jun 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article \"Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution\" from TradingKey states that relevant revenue data by business segment and region has not been disclosed by the company yet. It provides current stock information for Geron", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:09", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Geron Corp (GERN) stock, focusing on its historical dividends and stock splits. It indicates that Geron Corp has not distributed any dividends over the past five years and there is no data available for historical stock splits. The piece prese", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:09", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary", "summary": "This article summarizes Geron's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting the company's transition to a commercial stage with its drug RYTELO. RYTELO, approved for lower-risk MDS, is seeing increasing uptake and is positioned", "url": "https://quartr.com/events/geron-corporation-gern-goldman-sachs-47th-annual-global-healthcare-conference-2026_3Pg1Ia9c", "source_name": "Quartr", "published_at": "2026-06-12T19:39:14", "published_display": "12 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Stock Builds Momentum On Strong RYTELO Data", "summary": "Geron Corporation (GERN) stock is gaining momentum, trading up 10.36% due to positive real-world data for its drug RYTELO in lower-risk myelodysplastic syndromes (MDS). The data shows a 37.5% red blood cell transfusion independence rate, consistent with Phase 3 trials and suggest", "url": "https://stockstotrade.com/news/geron-corporation-gern-news-2026_06_11/", "source_name": "StocksToTrade", "published_at": "2026-06-12T17:09:01", "published_display": "12 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch", "summary": "Geron Corp has transitioned into a commercial-stage biotech after receiving FDA approval for its blood cancer drug imetelstat to treat lower-risk myelodysplastic syndromes (MDS) following positive Phase 3 data. The company's focus is now on the commercial launch, including pricin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-corp-stock-us3741631036-phase-3-data-keeps-focus-on-first/69509949", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T18:39:16", "published_display": "09 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did GERN Stock Tumble 10% Pre-Market Today?", "summary": "Geron's stock (GERN) tumbled over 10% pre-market after its fourth-quarter and full-year 2025 results showed total revenue and loss per share falling below analysts' estimates. Despite this, net product sales for its blood cancer therapy RYTELO reached $48 million in Q4, with sale", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-gern-stock-tumble-9-pre-market-today/cZRydItRIG2", "source_name": "Stocktwits", "published_at": "2026-06-06T14:39:35", "published_display": "06 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp stock (US3741631036): Focus on valuation as short interest eases", "summary": "Geron Corp shares are trading around the USD 1 mark on Nasdaq, with investors weighing recent pullbacks, short interest data, and valuation metrics. As of mid-May 2026, short interest saw a 7.3% decline, indicating a slight easing of bearish sentiment. Given Geron is a developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-corp-stock-us3741631036-focus-on-valuation-as-short-interest/69487435", "source_name": "AD HOC NEWS", "published_at": "2026-06-05T12:39:36", "published_display": "05 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN - Geron Corp Stock Price and Quote", "summary": "This article provides comprehensive stock information for Geron Corp (GERN), including its latest stock price, financial overview, key statistics, and a history of analyst ratings. It also lists recent news and press releases related to the company's financial results, corporate ", "url": "https://finviz.com/stock?t=GERN", "source_name": "Finviz", "published_at": "2026-06-04T14:09:05", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPOG40MGVHZE56U2dPUkwtZkFuaUhGaVFLLWVUTVJkNFhlcHMtTlFLUnNEcnZNQ2J2T2dZaXdzTWNKWnFnU2FLeFBBNEQ2RXE1SU5uX3RuT1FhODJuWmRqUDk1c1BhODRMM240WTYxLUdpTFc4dUx2aHEzYWJGY2VtcHJVdWJ1T2xQOXNzbHpubw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN SEC Filings - Geron Corp 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Geron Corp (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Key filings include the appointment of Harout Semerjian as the new CEO with details on his compensation and equi", "url": "https://www.stocktitan.net/sec-filings/GERN/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:09:04", "published_display": "03 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "Geron Corporation announced that its management team will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, to participate in a fireside chat. The biopharmaceutical company focuses on changing the course of blood cancer with its approved telomeras", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304303/0/en/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T18:40:03", "published_display": "03 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron plans Goldman Sachs healthcare fireside chat, webcast June 8", "summary": "Geron (Nasdaq: GERN) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, where company management will host a fireside chat on Monday, June 8, 2026, at 8:40 a.m. ET in Miami, Florida. A live and archived audio webcast of the event will be av", "url": "https://www.stocktitan.net/news/GERN/geron-to-participate-in-the-goldman-sachs-47th-annual-global-y6uzojbd9ag3.html", "source_name": "Stock Titan", "published_at": "2026-06-01T12:09:14", "published_display": "01 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron: Time To Reconsider This Oversold Biotech (NASDAQ:GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUGw5ZEZXZ1NKY2M4dmRHZWp3eDhvNUZobVRBdmZ3SklmQmI3NmVSdk5yYi01YUI4ZTJGdGRvTGtxekNWck9Ic3MzOHA4Wk9PWjQ0Q1o0QWJrY2hCTjJMdF9BemJIVWh1azMzNXI4N2lYc3lqMVBsNGFUNGxCU1pvOEpBLU1KU1JPT2ZQN0pfaXhfV3pKN0N3Mg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN - Aging Population Trends Will Expand Hematology Market Opportunity", "summary": "Analysts have slightly revised down Geron's price target due to more conservative assumptions regarding revenue growth, profit margins, and future P/E, though the intrinsic fair value estimate remains unchanged. Bullish analysts see this as a fine-tuning, while bearish analysts v", "url": "https://simplywall.st/narratives/iajwo4yv-aging-population-trends-will-expand-hematology-market-opportunity-sb98?bpId=4566410&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-27T22:40:06", "published_display": "27 May 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeFpMeFZ0ZTNicTdwWlc3UjkyWHdoaGNOa2JudkFSM2N4RV84RnNyYWtHV2s2azZsa0lEZG9IOVlVZTRGRC1QeTlDdHpoRmtoUzNtSVRPdmxpZnNKaU5hcm1ObnV0b3FnTkFQbDVSNVpYVmpQblduYXB4dl9qT3ZOWV9hNzVadms2d2tOMm9leGZjbVBwenNDdmdSUlpsdHhEN1BoTE5BYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNTEk0bUVBcjJKU01ETU5sTGdXX0lLX183OXl1ZG4xZU5sLXMxLVBmaW44bHFZNHlBdWtfOV9uLVZ4X1p0NHZlS1Y3ZmtwSnIzbWFHNWY1UnBsM1BtcGNkcDdkRktUeWRJZmNxMFlsWlBPTTFwQmdZdkpjbFMwcHk0NEVLQTh4RDZiUEdadmtNbw?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five new Geron hires receive options for 333,750 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZEZqaVd2N2wySDd5WUgzTS1ITXZKQTdBYzRfMFN4NVBQSnowVTJaNVhHbGE1c2kzRzhtdnZLSGVaVG9Ecmd3aF9SeGUxbVE1TFZUdXctMTE0eVFVV2lUMEJrRTFoeEJ3Yl8tYVhrMnV0RUpiWVF5R0pCbHJDbnFRU1l5RUJENGdZRVZTYWxwc0d1V3U4VEhBQ1VPN3Nib1hLcFI0cU9lQTRycWduSFRXS0d4bjk0cDZaVWdr?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Geron (GERN) to Present New Study Findings at EHA 2026 Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNYWd6bE1FTmlySVUtR1M3VGNQc01JWFlqY095NnhHWUlBR2s3a1FQbm1GSTRLTkszd29MSWkwOVM1UkZFMmlCeVFSMDJRcDNQdFJkQ2N4NXNjbEV4N2doRkJtNkc3Yk1IbXdaYXNndmFkYWhrSWJXM2ZSZ3pFLTdjNjFCQzV1SFR1bUJfTmlOWkFpT0N4LTBCaDFsUm1pUkZjOWpaTmZTVnVFeXpGWUtvcGRn?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNeHZBYnFTc2I3b2VSQXNnbVZhRkdYbUJqZGJRXy1DSWd4RE9YLWZxV1NSRXNKYS1FbmxnYlVkUHU1OVNTMjgxME5NOU8wVzdTT2hFSFZhck5OMWJBWUhuYjBmcURKQ3hXT241cE96T2hiYzRmOGhaYUxaaFBUNGxueW9XUU1BYWRYeGtmdnN3eGQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Geron (GERN) Valuation After Q1 2026 Earnings Beat And RYTELO Growth Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOVUJELTdWeWJHdEdqd1FOaWVpQ2lDZU1KakFobjcyWGpIc0JZMGpBb2M0c1Nqam9ZRUtHNW13bjZhemhlZXphdnByUXZrMlFuY0tLdmJ0WEZMT2VJNmV5VU5sNG1VeUs0SWpJRXNTY0w4OWFZb19qT3dGeFE2MWUzQmJ3V2s4V0cyU2RZTWVSSjFGLTh1Zm1pMVJqUGtJN3pF?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVmpJbkhCRzRReG51dkE1bmZkS3dFMVNuMXl0QlgtNndQdVlwTGZSbXgxeDFNRzE5ekJQNGFkbGUydEJlUG1kVDN1NWU0R2VibTJSbzBsYzNEeHdsaE9HMGV6LXBNeElBNDZXcl9pRzJ4N0s1WFAzWFRuUExrUE5mTXVJa00yb1hhd3Nmb2d4d0VjaEtjd0ktWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Geron\u2019s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Q1 Loss Sharply Narrows And Tests Skeptical Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNSlhNaHd4a0FLQ1k4TFdzV2IzWnp4MUJGVl9udDFSVXRnaEtmNHdJY3plUENpYlpLYXRYRnBuLVhDRTRBdXhPWmxrSm4yY2d1SXVzeUh5MVA2X25QMjVQRFQzX3pTM09mZlYxZDNBS3QxSk5nWHU5aTNoUUFvMk5JMXhZMUY2clNIQ1k5NlRMcnJzRDRmMnc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Geron Adds Chief Legal Officer As Equity Incentives And Valuation Draw Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Geron legal chief gets option to buy 2.5M shares at $1.73", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY0wzMW9kRVY1MzVDQWFwVHAwMlN5TEJ3TzFRbFZCVUhybTMyTHBKa25ZaVMta25ZRWI5RlRucmE5MFdSR0pvWEVJdmtpdVdVVHVLeXAxc1IwTGw4YkYxOERrc1lXR2ZDb29fQV8zbk5fNmdjMDctdTF2NmFKQkI4MklGX2k3aGxGQUVwbFlPTXBNNWt2NkxXaDRnWFhZMWxYMHdIbWIxR1VmRFYtR1h3Q0VjblNxSkhyYkhpWmM5VFA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOUF9XbEpnMDRGZEJTLWdCU0tqcjdJYlRSV090NV9yZzJsQ2d6TUc5QjFLdVpXb2twYXgyNkNyTjNWeE42MkFrNVNwN0UyUENyOWVMWlRJdkZMZzdZRnhJamlYUlQ4Qnh3UWxib2UwM1dxTTJuNGpKeXJ4RE1lZmpweDZfdnA4N1c4aEtqVnAxbTdKaGpjeFFELWVXaTRWUEFyTFVOMkdpcw?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Geron (GERN) Pricing Look Attractive After Recent Share Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNNXA4dmZtbm9fQ1U4R2ZwbTlRSEpHRTA1OHhuM0JucllqdllkcUlWamhsNEQzeXBqYTkwMXJEeWxkaENBOFJ2cjdURVVTTWsxRHphYWlTUUl6MDV2dGFNY0g1TXd0dVRBMlZ4SnRSX0FVa2N5azhlMThYWE5wTjZQUFZBdmV4SVk?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZEs4bWtVRFd1QkZ1NzhQTUs5MTRLSWZoeTVSTUx1YTJWNEswOWNMWGRreXRPWTc2UjBsandval8yUk01T2xWU1c4U1Z5d1Y4YkJFT2NacVUtaG1KOWt1czA4ZDl0V2o1WkxBVEVyclZWNHNvblJ1NlMxOW1hd2pDcTlR?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdzA5UHZkQnZ6ZXU4VWpKNjAtSUYyZTcwUE1pQjByQUFlUWZsNzJlWVZ1Skpxc0puVlE0cmpnbDRMWlJONVQ1VG5HdHdJd1pJb1d3Vm92TmxIQmFtaU5hbmlGN24zdjh1UDN4dTVqRHVGOXBrbEg0Y1M1dXBjN0hUWkxhMzR5T19lc043bC13UGVtZWJvQURlazdVejFxTUd4TkNKNGJacUJ4RWdxb3NMTHdETE1GdkNKMjJxTw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Geron (GERN) Is Signaling Commercial Ambition, Not Just Handing Out Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxNN3FHeWZmdGRzOUFOUGlFQWlpVWlfYlRmTUMwOHZaTG5QZ2I0VEp1MFNWd1N1amxNdDNMTWlCT2hnc1dmM2tSY0Z0NTR3SzZsY3E1RnZIdHBwT2hvY1FzOVRWV1lqSW9mZHB4cGlIUklKN3pMWGd3Q1l5ZlFTdWRyZHhKNW9NaGNKY3dObmFqd1dyX3ctOE9yLWlsNTdZN1dmU2JZc3dfRzVuek1lNkF0TGgtSW9LSzJ3Q0tGTFRRQmJPREpCTUhCNG5EX0N4V0w0NnpQVHlqYzRWNmlKSlowNGs5Wk9Cd3N4ZkNDakJXSE1EZzdKaHltMVJwdm84NFlrMHU5T3VRT0tqeWZ6cjdGaWM5UE1rT0xMWF9wYTM5dmxnMnpVWk1TYmdGOE5jaGQyRFlMRFhtOWoyd2JKNlZ0NUZLZ2_SAcQCQVVfeXFMTTdxR3lmZnRkczlBTlBpRUFpaVVpX2JUZk1DMDh2WkxuUGdiNFRKdTBTVndTdWpsTXQzTE1pQk9oZ3NXZjNrUmNGdDU0d0s2bGNxNUZ2SHRwcE9ob2NRczlUVldZaklvZmRweHBpSFJJSjd6TFhnd0NZeWZRU3VkcmR4SjVvTWhjSmN3Tm5handXcl93LThPci1pbDU3WTdXZlNiWXN3X0c1bnpNZTZBdExoLUlvS0syd0NLRkxUUUJiT0RKQk1IQjRuRF9DeFdMNDZ6UFR5amM0VjZpSkpaMDRrOVpPQndzeGZDQ2pCV0hNRGc3Smh5bTFScHZvODRZazB1OU91UU9LanlmenI3RmljOVBNa09MTFhfcGEzOXZsZzJ6VVpNU2JnRjhOY2hkMkRZTERYbTlqMndiSjZWdDVGS2dv?oc=5", "source_name": "AlphaStreet", "published_at": "2026-07-15T11:50:22+00:00", "published_display": "15 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Geron Corporation announced an inducement grant in the form of a stock option to purchase 1,700,000 shares of its common stock for Chinmaya Rath, the new Chief Business Officer. The grant, made on July 13, 2026, has an exercise price of $1.42 per share and vests over four years, ", "url": "https://sg.finance.yahoo.com/news/geron-corporation-reports-inducement-grant-202600682.html", "source_name": "Market source", "published_at": "2026-07-14T20:26:00", "published_display": "14 Jul 2026 20:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron's New Business Chief Gets Option on 1.7M Shares", "summary": "Geron (GERN) granted a stock option to its new Chief Business Officer, Chinmaya Rath, entitling him to purchase 1.7 million shares of common stock. This inducement award, detailed in a recent report, has an exercise price of $1.42 per share, matching the closing price on the gran", "url": "https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-do92xlx06muk.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:17:30", "published_display": "14 Jul 2026 20:17", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Grants Inducement Stock Options to New Employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPNVFOSElFdXl0R2l0NmNWWFhaeXNaUmd5ajJlNzhwRkNrNDQ0TkFUV2h1bjJnQUZHUzlpbVo2bmJXSF8tV3hoNkw4ZV9SOXpLOThsQk50QnFWemt0RWd5QXRBQjhTOHNxSG5EMEpGNUp4ZEZxTmZUaTEwMUE4bG5KUFhMdF9kMEI0T252T2VKT3Nzc1liU2RxRWNERVBWX3F1?oc=5", "source_name": "Market source", "published_at": "2026-07-14T10:34:02+00:00", "published_display": "14 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth", "summary": "Geron (Nasdaq: GERN) has appointed Chinmaya Rath as its new Chief Business Officer, effective July 13, 2026. Rath brings over 25 years of biopharma leadership experience from companies like Novartis and Cellworks, and will focus on maximizing RYTELO's global value and expanding G", "url": "https://www.stocktitan.net/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-39rh8q718wzc.html", "source_name": "Stock Titan", "published_at": "2026-07-13T17:12:17", "published_display": "13 Jul 2026 17:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron appoints Chinmaya Rath as chief business officer", "summary": "Geron Corporation has appointed Chinmaya Rath as Chief Business Officer, leveraging his 25 years of biopharmaceutical leadership experience from companies like Novartis and Cellworks. Rath will contribute to the commercial-stage company, which markets RYTELO for myelodysplastic s", "url": "https://www.investing.com/news/company-news/geron-appoints-chinmaya-rath-as-chief-business-officer-93CH-4788440", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:41", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Announces Appointment of Chinmaya Rath as Chief Business Officer", "summary": "Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharmaceutical leadership experience and will focus on maximizing the value of Geron's drug RYTELO and exploring new opportunities to expand the company's hematology p", "url": "https://ca.finance.yahoo.com/news/geron-announces-appointment-chinmaya-rath-120000011.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-13T12:09:41", "published_display": "13 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Geron Corporation Stocks", "summary": "This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Geron Corporation (0IV3 on the London Stock Exchange). It details various ETFs, including their market value, weight of Geron stock, issuer, management style, expense ratio, assets unde", "url": "https://www.tradingview.com/symbols/LSE-0IV3/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T00:40:51", "published_display": "09 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron stock leans on its myelofibrosis story", "summary": "Geron's stock performance is closely linked to the commercial rollout of its lead product, Rytelo, for myelofibrosis. The biotechnology company, listed on Nasdaq, focuses on blood-cancer therapies, with execution in sales adoption and physician uptake being crucial for its market", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-stock-leans-on-its-myelofibrosis-story/69679846", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:43:46", "published_display": "03 Jul 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN News | GERON CORP (NASDAQ:GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1HNTJFakppZ0QtdER5ZEZMVEdnNVIzaXN2eUhyZXRTaUd6ZTc5TzF6ejBFRDhuMlczWkkwRVl2S0NwOTJFVHhwX2RLbmJ1akE0NE80a1Y0THpQSTQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:01+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees", "summary": "Geron Corp. (GERN) director Robert J. Spiegel received a grant of 6,103 shares of common stock on June 30, 2026, as compensation for his quarterly board retainer and committee fees. The shares were valued at $1.28 each, based on the closing price of the company's stock that day. ", "url": "https://www.stocktitan.net/sec-filings/GERN/form-4-geron-corp-insider-trading-activity-2d487d1a043b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:39", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Geron Corporation For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Geron Corporation on July 1st. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a ", "url": "https://ca.investing.com/news/stock-market-news/form-4-geron-corporation-for-1-july-93CH-4717234", "source_name": "Investing.com Canada", "published_at": "2026-07-01T21:40:39", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSndRWF8zQVVlWFNnQVJic2N1OXFqOERxV2I0bW5Nc2U0OUMwckxETjJISy1pRDVobDliM1FPWjRiMktITDJuX0FOUjFDSGhXeWhEdTJQRTdnNUFjS1NNUGZjYmdfSlBIaGphVVZMSW53eTd3LUZRNGR2RmpzYWdwanZEUFhfdmRqbHA0Z0FDVENjWi1Nd1FVV2Z1TXNJajE4cnZGc1ZfaEZqVXdWMDJZVVdwVmFBTExS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Geron Corporation (GERN) stock, indicating current stock performance, analyst opinions, and key financial metrics. It highlights GERN's present stock price, recent percentage changes, historical highs and lows, and upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-GERN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:49", "published_display": "25 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Stock Steadies As Geron Builds Commercial Momentum", "summary": "Geron Corporation (GERN) stock is experiencing a 7.14% increase due to positive sentiment surrounding its late-stage blood cancer therapy. The company has granted significant stock options to new employees, signaling aggressive talent acquisition, and is demonstrating commercial ", "url": "https://stockstotrade.com/news/geron-corporation-gern-news-2026_06_22/", "source_name": "StocksToTrade", "published_at": "2026-06-22T17:40:18", "published_display": "22 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Geron Corporation announced inducement grants of stock options to eight new employees, as specified under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. Geron is a comm", "url": "https://www.manilatimes.net/2026/06/19/tmt-newswire/globenewswire/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2368826", "source_name": "The Manila Times", "published_at": "2026-06-20T10:39:38", "published_display": "20 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron dangles 690,000 options to recruit eight new employees", "summary": "Geron (Nasdaq: GERN) granted 690,000 stock options to eight new employees as inducement awards on June 17, 2026. The options have an exercise price of $1.23 per share, matching the closing price on the grant date, and vest over four years. This move resulted in a 6.35% increase i", "url": "https://www.stocktitan.net/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-ex89egsh2038.html", "source_name": "Stock Titan", "published_at": "2026-06-18T15:40:35", "published_display": "18 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Geron Corp (GERN), listing major institutional shareholders like RA Capital Management and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent changes in shareholdings ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T15:13:49", "published_display": "18 Jun 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article \"Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution\" from TradingKey states that relevant revenue data by business segment and region has not been disclosed by the company yet. It provides current stock information for Geron", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:09", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Geron Corp (GERN) stock, focusing on its historical dividends and stock splits. It indicates that Geron Corp has not distributed any dividends over the past five years and there is no data available for historical stock splits. The piece prese", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gern/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:09", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary", "summary": "This article summarizes Geron's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting the company's transition to a commercial stage with its drug RYTELO. RYTELO, approved for lower-risk MDS, is seeing increasing uptake and is positioned", "url": "https://quartr.com/events/geron-corporation-gern-goldman-sachs-47th-annual-global-healthcare-conference-2026_3Pg1Ia9c", "source_name": "Quartr", "published_at": "2026-06-12T19:39:14", "published_display": "12 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN Stock Builds Momentum On Strong RYTELO Data", "summary": "Geron Corporation (GERN) stock is gaining momentum, trading up 10.36% due to positive real-world data for its drug RYTELO in lower-risk myelodysplastic syndromes (MDS). The data shows a 37.5% red blood cell transfusion independence rate, consistent with Phase 3 trials and suggest", "url": "https://stockstotrade.com/news/geron-corporation-gern-news-2026_06_11/", "source_name": "StocksToTrade", "published_at": "2026-06-12T17:09:01", "published_display": "12 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch", "summary": "Geron Corp has transitioned into a commercial-stage biotech after receiving FDA approval for its blood cancer drug imetelstat to treat lower-risk myelodysplastic syndromes (MDS) following positive Phase 3 data. The company's focus is now on the commercial launch, including pricin", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-corp-stock-us3741631036-phase-3-data-keeps-focus-on-first/69509949", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T18:39:16", "published_display": "09 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did GERN Stock Tumble 10% Pre-Market Today?", "summary": "Geron's stock (GERN) tumbled over 10% pre-market after its fourth-quarter and full-year 2025 results showed total revenue and loss per share falling below analysts' estimates. Despite this, net product sales for its blood cancer therapy RYTELO reached $48 million in Q4, with sale", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-gern-stock-tumble-9-pre-market-today/cZRydItRIG2", "source_name": "Stocktwits", "published_at": "2026-06-06T14:39:35", "published_display": "06 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corp stock (US3741631036): Focus on valuation as short interest eases", "summary": "Geron Corp shares are trading around the USD 1 mark on Nasdaq, with investors weighing recent pullbacks, short interest data, and valuation metrics. As of mid-May 2026, short interest saw a 7.3% decline, indicating a slight easing of bearish sentiment. Given Geron is a developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/geron-corp-stock-us3741631036-focus-on-valuation-as-short-interest/69487435", "source_name": "AD HOC NEWS", "published_at": "2026-06-05T12:39:36", "published_display": "05 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN - Geron Corp Stock Price and Quote", "summary": "This article provides comprehensive stock information for Geron Corp (GERN), including its latest stock price, financial overview, key statistics, and a history of analyst ratings. It also lists recent news and press releases related to the company's financial results, corporate ", "url": "https://finviz.com/stock?t=GERN", "source_name": "Finviz", "published_at": "2026-06-04T14:09:05", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPOG40MGVHZE56U2dPUkwtZkFuaUhGaVFLLWVUTVJkNFhlcHMtTlFLUnNEcnZNQ2J2T2dZaXdzTWNKWnFnU2FLeFBBNEQ2RXE1SU5uX3RuT1FhODJuWmRqUDk1c1BhODRMM240WTYxLUdpTFc4dUx2aHEzYWJGY2VtcHJVdWJ1T2xQOXNzbHpubw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN SEC Filings - Geron Corp 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Geron Corp (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Key filings include the appointment of Harout Semerjian as the new CEO with details on his compensation and equi", "url": "https://www.stocktitan.net/sec-filings/GERN/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:09:04", "published_display": "03 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "Geron Corporation announced that its management team will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, to participate in a fireside chat. The biopharmaceutical company focuses on changing the course of blood cancer with its approved telomeras", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304303/0/en/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T18:40:03", "published_display": "03 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron plans Goldman Sachs healthcare fireside chat, webcast June 8", "summary": "Geron (Nasdaq: GERN) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, where company management will host a fireside chat on Monday, June 8, 2026, at 8:40 a.m. ET in Miami, Florida. A live and archived audio webcast of the event will be av", "url": "https://www.stocktitan.net/news/GERN/geron-to-participate-in-the-goldman-sachs-47th-annual-global-y6uzojbd9ag3.html", "source_name": "Stock Titan", "published_at": "2026-06-01T12:09:14", "published_display": "01 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron: Time To Reconsider This Oversold Biotech (NASDAQ:GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUGw5ZEZXZ1NKY2M4dmRHZWp3eDhvNUZobVRBdmZ3SklmQmI3NmVSdk5yYi01YUI4ZTJGdGRvTGtxekNWck9Ic3MzOHA4Wk9PWjQ0Q1o0QWJrY2hCTjJMdF9BemJIVWh1azMzNXI4N2lYc3lqMVBsNGFUNGxCU1pvOEpBLU1KU1JPT2ZQN0pfaXhfV3pKN0N3Mg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GERN - Aging Population Trends Will Expand Hematology Market Opportunity", "summary": "Analysts have slightly revised down Geron's price target due to more conservative assumptions regarding revenue growth, profit margins, and future P/E, though the intrinsic fair value estimate remains unchanged. Bullish analysts see this as a fine-tuning, while bearish analysts v", "url": "https://simplywall.st/narratives/iajwo4yv-aging-population-trends-will-expand-hematology-market-opportunity-sb98?bpId=4566410&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-27T22:40:06", "published_display": "27 May 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeFpMeFZ0ZTNicTdwWlc3UjkyWHdoaGNOa2JudkFSM2N4RV84RnNyYWtHV2s2azZsa0lEZG9IOVlVZTRGRC1QeTlDdHpoRmtoUzNtSVRPdmxpZnNKaU5hcm1ObnV0b3FnTkFQbDVSNVpYVmpQblduYXB4dl9qT3ZOWV9hNzVadms2d2tOMm9leGZjbVBwenNDdmdSUlpsdHhEN1BoTE5BYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNTEk0bUVBcjJKU01ETU5sTGdXX0lLX183OXl1ZG4xZU5sLXMxLVBmaW44bHFZNHlBdWtfOV9uLVZ4X1p0NHZlS1Y3ZmtwSnIzbWFHNWY1UnBsM1BtcGNkcDdkRktUeWRJZmNxMFlsWlBPTTFwQmdZdkpjbFMwcHk0NEVLQTh4RDZiUEdadmtNbw?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five new Geron hires receive options for 333,750 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZEZqaVd2N2wySDd5WUgzTS1ITXZKQTdBYzRfMFN4NVBQSnowVTJaNVhHbGE1c2kzRzhtdnZLSGVaVG9Ecmd3aF9SeGUxbVE1TFZUdXctMTE0eVFVV2lUMEJrRTFoeEJ3Yl8tYVhrMnV0RUpiWVF5R0pCbHJDbnFRU1l5RUJENGdZRVZTYWxwc0d1V3U4VEhBQ1VPN3Nib1hLcFI0cU9lQTRycWduSFRXS0d4bjk0cDZaVWdr?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) to Present New Study Findings at EHA 2026 Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNYWd6bE1FTmlySVUtR1M3VGNQc01JWFlqY095NnhHWUlBR2s3a1FQbm1GSTRLTkszd29MSWkwOVM1UkZFMmlCeVFSMDJRcDNQdFJkQ2N4NXNjbEV4N2doRkJtNkc3Yk1IbXdaYXNndmFkYWhrSWJXM2ZSZ3pFLTdjNjFCQzV1SFR1bUJfTmlOWkFpT0N4LTBCaDFsUm1pUkZjOWpaTmZTVnVFeXpGWUtvcGRn?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNeHZBYnFTc2I3b2VSQXNnbVZhRkdYbUJqZGJRXy1DSWd4RE9YLWZxV1NSRXNKYS1FbmxnYlVkUHU1OVNTMjgxME5NOU8wVzdTT2hFSFZhck5OMWJBWUhuYjBmcURKQ3hXT241cE96T2hiYzRmOGhaYUxaaFBUNGxueW9XUU1BYWRYeGtmdnN3eGQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Geron (GERN) Valuation After Q1 2026 Earnings Beat And RYTELO Growth Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPMS1lTENnTllEWlZoel80dzctQ0JiRzlIQmc5YTZWbWxiVGVmZ21jTzYwNGpWenBsdGh6a3ZmeHY1SjZPWDJDdnhuNjRYWGVXbG9GRVRwZks3X2lsc3RSSVdCOV81dVloMXJoWUJaSG9PZVhvMkVuam1NMEpvQmdqajBoWFE5NkxOX2V5T3VGaTlRTUtpMHhvdHp6cGVMakpXMGdFenJDR1RJbzA0d0g5UGJFdVJvdF9YUXNKSDIwOV9ZLUd2TTJrOGZ5RHRKemJEUW9iV0xB0gHbAUFVX3lxTE9KRTU4d001TEpxVnE0M3dldVJINkFvUDBEUGFETmpOZzNwZnFGVmpVOXZmNzlRSTBFQUo1Vk9XY3pNaFpXeUhEVURmelN0cHQxNHRYdzR0RHF3aTZCV2FHSmdzVjhHNE5kaWx1a3dmWWVRQm5QaVdaNGNYSlB4aU9nMjZMQ2JVS1lBTjVrek5fZVBpQ2ZzeTFsN05aNlVXSlhxN1F6cWdJdHJyLXdKZFJ3MUNWZlczQ3VQUEhkTWh0bXQ4Q3ZtbWJYZXNhX042TWhzZnotdktRNHpnWQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOVUJELTdWeWJHdEdqd1FOaWVpQ2lDZU1KakFobjcyWGpIc0JZMGpBb2M0c1Nqam9ZRUtHNW13bjZhemhlZXphdnByUXZrMlFuY0tLdmJ0WEZMT2VJNmV5VU5sNG1VeUs0SWpJRXNTY0w4OWFZb19qT3dGeFE2MWUzQmJ3V2s4V0cyU2RZTWVSSjFGLTh1Zm1pMVJqUGtJN3pF?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVmpJbkhCRzRReG51dkE1bmZkS3dFMVNuMXl0QlgtNndQdVlwTGZSbXgxeDFNRzE5ekJQNGFkbGUydEJlUG1kVDN1NWU0R2VibTJSbzBsYzNEeHdsaE9HMGV6LXBNeElBNDZXcl9pRzJ4N0s1WFAzWFRuUExrUE5mTXVJa00yb1hhd3Nmb2d4d0VjaEtjd0ktWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Geron\u2019s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Q1 Loss Sharply Narrows And Tests Skeptical Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNSlhNaHd4a0FLQ1k4TFdzV2IzWnp4MUJGVl9udDFSVXRnaEtmNHdJY3plUENpYlpLYXRYRnBuLVhDRTRBdXhPWmxrSm4yY2d1SXVzeUh5MVA2X25QMjVQRFQzX3pTM09mZlYxZDNBS3QxSk5nWHU5aTNoUUFvMk5JMXhZMUY2clNIQ1k5NlRMcnJzRDRmMnc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Adds Chief Legal Officer As Equity Incentives And Valuation Draw Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Geron legal chief gets option to buy 2.5M shares at $1.73", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY0wzMW9kRVY1MzVDQWFwVHAwMlN5TEJ3TzFRbFZCVUhybTMyTHBKa25ZaVMta25ZRWI5RlRucmE5MFdSR0pvWEVJdmtpdVdVVHVLeXAxc1IwTGw4YkYxOERrc1lXR2ZDb29fQV8zbk5fNmdjMDctdTF2NmFKQkI4MklGX2k3aGxGQUVwbFlPTXBNNWt2NkxXaDRnWFhZMWxYMHdIbWIxR1VmRFYtR1h3Q0VjblNxSkhyYkhpWmM5VFA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOUF9XbEpnMDRGZEJTLWdCU0tqcjdJYlRSV090NV9yZzJsQ2d6TUc5QjFLdVpXb2twYXgyNkNyTjNWeE42MkFrNVNwN0UyUENyOWVMWlRJdkZMZzdZRnhJamlYUlQ4Qnh3UWxib2UwM1dxTTJuNGpKeXJ4RE1lZmpweDZfdnA4N1c4aEtqVnAxbTdKaGpjeFFELWVXaTRWUEFyTFVOMkdpcw?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Geron (GERN) Pricing Look Attractive After Recent Share Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNNXA4dmZtbm9fQ1U4R2ZwbTlRSEpHRTA1OHhuM0JucllqdllkcUlWamhsNEQzeXBqYTkwMXJEeWxkaENBOFJ2cjdURVVTTWsxRHphYWlTUUl6MDV2dGFNY0g1TXd0dVRBMlZ4SnRSX0FVa2N5azhlMThYWE5wTjZQUFZBdmV4SVk?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZEs4bWtVRFd1QkZ1NzhQTUs5MTRLSWZoeTVSTUx1YTJWNEswOWNMWGRreXRPWTc2UjBsandval8yUk01T2xWU1c4U1Z5d1Y4YkJFT2NacVUtaG1KOWt1czA4ZDl0V2o1WkxBVEVyclZWNHNvblJ1NlMxOW1hd2pDcTlR?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdzA5UHZkQnZ6ZXU4VWpKNjAtSUYyZTcwUE1pQjByQUFlUWZsNzJlWVZ1Skpxc0puVlE0cmpnbDRMWlJONVQ1VG5HdHdJd1pJb1d3Vm92TmxIQmFtaU5hbmlGN24zdjh1UDN4dTVqRHVGOXBrbEg0Y1M1dXBjN0hUWkxhMzR5T19lc043bC13UGVtZWJvQURlazdVejFxTUd4TkNKNGJacUJ4RWdxb3NMTHdETE1GdkNKMjJxTw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 58, "sentiment_summary": {"positive": 18, "negative": 5, "neutral": 35, "score": 56, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.5, "latest_week": "2026-07-10", "one_week_move": 10.3, "four_week_move": 30.4, "twelve_week_move": -10.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.543235, "market_dynamics_buy_signal": false, "relative_strength": -6.456709, "fair_value_gap": -37.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.0037, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.3% over one week, +30.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "TradingView", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "StocksToTrade", "count": 2}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+10.3% over one week, +30.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Geron (GERN) Is Signaling Commercial Ambition, Not Just Handing Out Options"}], "updated_at": "2026-07-16T11:50:15.716356+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}